Ozempic and GLP-1: The New Obesity Drug Boom | FULL DOCUMENTARY

Ozempic and other GLP-1 analogues have become widely discussed treatments for obesity. Originally developed for diabetes, these medications mimic the hormone GLP-1, which signals satiety to the brain and helps regulate appetite. Doctors and researchers explain how these drugs affect hunger, metabolism, and weight loss, while patients describe their experiences with treatments such as liraglutide and semaglutide. Through testimonies from patients including Luciano Casto, Marie-France, Leticia, Adriana Poli, and Camille Aquillon, the documentary follows different paths through obesity treatment. Specialists from the Centre de l’obésité at the CHUV and the Hôpitaux universitaires de Genève, including Dre Lucie Favre, Prof. Zoltan Pataky, Dre Styliani Mantziari, and Dr Michel Cauderay, discuss how these medications are used alongside medical follow-up, nutrition guidance, and psychological support. The film also examines questions surrounding long-term treatment, prescription criteria, reimbursement rules, and the growing market for GLP-1 drugs such as Ozempic, Wegovy, Saxenda, and Victoza. Watch to explore how these new treatments are changing the medical approach to obesity. Documentary: Enquête sur la piqûre qui fait maigrir Directed by: Vanessa Goetelen Production: RADIO TELEVISION SUISSE (2024) Ce programme est disponible sur https://www.rts.ch/play/tv #ozempic #glp1 #weightlossdrugs #obesitytreatment #obesitymedicine #semaglutide #wegovy #medicaldocumentary #healthdocumentary #pharmaindustry #obesityscience #weightlossresearch #publichealth